Revenue

9 Months Ended

Jun. 30, 2020

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by operating segment, excluding sales taxes collected and remitted to governmental authorities.

	Three Months Ended				Nine Months Ended
	June 30,				June 30,
(Dollars in thousands)	2020		2019		2020		2019
Medical Device
Product sales	$	5,763	$	4,500	$	16,240	$	13,836
Royalties		4,752		9,605		20,365		25,603
Research, development and other		2,353		2,821		7,215		8,016
License fees		7,646		2,019		10,402		6,049
Total Revenue — Medical Device		20,514		18,945		54,222		53,504
In Vitro Diagnostics
Product sales		6,224		5,370		17,491		15,672
Other		145		29		608		85
Total Revenue — In Vitro Diagnostics		6,369		5,399		18,099		15,757
Total Revenue	$	26,883	$	24,344	$	72,321	$	69,261

Contract Assets, Deferred Revenue and Remaining Performance Obligations

Contract asset balances consist of estimated sales-based royalties earned but not collected at each balance sheet date and are subject to timing fluctuations at the end of a given period. The Company’s deferred revenue, or contract liability, is primarily related to the upfront and milestone payments received pursuant to the collaborative license and commercialization agreement (the “Abbott Agreement”) with Abbott Vascular, Inc. (“Abbott”) for the Company’s SurVeil™ drug-coated balloon product (“SurVeil DCB”) discussed in Note 3.

As of June 30, 2020, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more totaled approximately $17.5 million. These remaining performance obligations relate to the Abbott Agreement (Note 3), exclude contingent milestone payments under the Abbott Agreement, and are expected to be recognized over the next five years through fiscal 2025 as services, principally the TRANSCEND clinical trial, are completed.